Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I

• 25
• wherein
• W is SO2, CO, CONH, CSNH or (CH2)x;
• X is O, SOy or NR13;
• Y is CR14 or N;
• Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
• m and x are each independently 0 or an integer of 1, 2 or 3;
• n and p are each independently an integer of 1, 2 or 3;
• R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
• R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
• R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R12 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
• y and w are each 0 or an integer of 1 or 2;
• R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
• R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
• R17 and R29 are each independently H or a C1-C6alkyl, C2-C6 alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C1-C6 alkyl group;
• R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
• and
• R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group;
• or
• the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I

• 26
• wherein
• W is SO2, CO, CONH, CSNH or (CH2)x;
• X is O, SOy or NR13;
• Y is CR14 or N;
• Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
• m and x are each independently 0 or an integer of 1, 2 or 3;
• n and p are each independently an integer of 1, 2 or 3;
• R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
• R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
• R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R12 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
• y and w are each 0 or an integer of 1 or 2;
• R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
• R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
• R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, 3—C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C1-C6alkyl group;
• R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
• and
• R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group;
• or
• the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

A compound of formula XVI

• 29
• wherein
• X is O, SOy or NR13;
• Y is CR14 or N;
• Z is CR5 or N with the proviso that when Y is N then Z must be CR15;
• m is 0 or an integer of 1, 2 or 3;
• n and p are each independently an integer of 1, 2 or 3;
• R1 is halogen, CN, OR16, CONR17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
• R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
• R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl or cycloheteroalkyl group each optionally substituted;
• R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
• R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
• R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
• R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C1-C6alkyl group;
• R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
• and
• R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group;
• or
• the stereoisomers thereof or the pharmaceutically acceptable salts thereof.